<?xml version="1.0" encoding="UTF-8"?>
<p>The utmost urgency required to effectively contain the epidemic has dramatically changed the perception of the need for an Ebola vaccine, and the global response has resulted in substantial funds being released for Ebola.
 <xref rid="bib63" ref-type="bibr">
  <sup>63</sup>
 </xref> This development is accompanied by renewed interest from researchers and pharmaceutical companies. Interestingly, some drug companies have insisted on securing indemnity from government against loss or damages that might follow use of the products developed from fast-tracked clinical trials.
 <xref rid="bib64" ref-type="bibr">
  <sup>64</sup>
 </xref>
</p>
